
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Oncol. , 10 January 2023
Sec. Breast Cancer
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1118572
This article is a correction to:
TGF-β1 promotes human breast cancer angiogenesis and malignant behavior by regulating endothelial-mesenchymal transition
A corrigendum on
TGF-β1 promotes human breast cancer angiogenesis and malignant behavior by regulating endothelial-mesenchymal transition.
by Li Z-X, Chen J-X, Zheng Z-J, Cai W-J, Yang X-B, Huang Y-Y, Gong Y, Xu F, Chen Y-S and Lin L (2022) 12:1051148. doi: 10.3389/fonc.2022.1051148
Error in Figure/Table
In the published article, there was an error in Figure 1 High expression of MVD predicted unfavorable prognosis of IDC patients. as published. In Figure 1B, the title of X axis was “Specificity”, it should be corrected to “1-Specificity”. The corrected Figure 1 High expression of MVD predicted unfavorable prognosis of IDC patients. and its caption appear below.
Figure 1 High expression of MVD predicted unfavorable prognosis of IDC patients. (A) Representative images of immunohistochemical (IHC) staining of vWF and CD34 in samples from breast invasive ductal carcinoma (IDC) patients. (B) ROC curve of the CD34 and vWF by the DFS of IDC patients. (C, D) Kaplan-Meier analysis of DFS and OS of IDC patients from our cohort by vWF and CD34.
In the published article, there was an error in Figure 2 MVD level is positively correlated with EndMT markers in breast cancer. as published. In Figure 2A, B, the red “#” and green “*” were missing. The corrected Figure 2 MVD level is positively correlated with EndMT markers in breast cancer. and its caption appear below.
Figure 2 MVD level is positively correlated with EndMT markers in breast cancer. (A, B) Representative images of double-IHC staining of vWF, CD34 (brown, with red “#”) and either α-SMA, FSP-1 or Vimentin (red, with green “*”) in samples from IDC patients. (C–G) Kaplan-Meier analysis of DFS and OS of IDC patients from our cohort by α-SMA, FSP-1, Vimentin, VE-Cadherin and Fibronectin.
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: TGF-β1, EndMT, angiogenesis, breast cancer, BCSLC, dorsal skinfold window chamber
Citation: Li Z-X, Chen J-X, Zheng Z-J, Cai W-J, Yang X-B, Huang Y-Y, Gong Y, Xu F, Chen Y-S and Lin L (2023) Corrigendum: TGF-β1 promotes human breast cancer angiogenesis and malignant behavior by regulating endothelial-mesenchymal transition. Front. Oncol. 12:1118572. doi: 10.3389/fonc.2022.1118572
Received: 07 December 2022; Accepted: 12 December 2022;
Published: 10 January 2023.
Edited and Reviewed by:
Donghong Zhang, Emory University, United StatesCopyright © 2023 Li, Chen, Zheng, Cai, Yang, Huang, Gong, Xu, Chen and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ling Lin, bGxpbmNAMTYzLm5ldA==; Yong-Song Chen, eW9uZ3NvbmdjaGVuQDEyNi5jb20=
†These authors have contributed equally to this work
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.